US biopharma Corcept Therapeutics (Nasdaq: CORT) says its Phase III ROSELLA trial met its overall survival primary endpoint ...

Japanese drugmaker Daiichi Sankyo has appointed Veronika Rozehnal to succeed Jürgen Müller as the Head of the Translational ...

Janux Therapeutics’ shares closed up 14% at $15.14, after it announced a collaboration and exclusive worldwide license ...

Privately-held UK drug developer Ellipses Pharma has entered into a collaboration and licence agreement with China-based Innolake Biopharm to develop a clinical stage first-in-class antibody drug ...

UK pharma major GSK’s Nucala (mepolizumab) has recently received approval in China as add-on maintenance treatment for adults ...

The Gates Foundation, Novo Nordisk Foundation, and Wellcome have said they will award $60 million in new grant funding over ...

San Francisco-based Mendra, a biopharma aiming to advance promising therapies for rare disease medicines, has announced its ...

US clinical-stage biotech Corxel Pharmaceuticals, dedicated to developing innovative therapies for patients with ...

DelveInsight says the cystinosis treatment market across the USA, EU4, UK and Japan totaled about $250 million in 2024, with ...

US pharma major Gilead Sciences (Nasdaq: GILD) says The New England Journal of Medicine has published full Phase III data for ...

US healthcare company Sagebrush Health Services, a non-profit organization serving more than 10,000 Nevada patients, has ...

Texas, USA-based IntraBio revealed that the European Commission granted marketing authorization to Aqneursa (levacetylleucine ...